SOURCE: Kleo Pharmaceuticals Inc.

Kleo Pharmaceuticals Inc.

September 22, 2016 03:00 ET

Kleo Pharmaceuticals Inc. Appoints Roy Prieb as Chief Operating Officer and Chief Financial Officer

NEW HAVEN, CT--(Marketwired - September 22, 2016) - Kleo Pharmaceuticals Inc., a biotechnology company pioneering a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and infectious diseases, announced today the appointment of Roy Prieb as Chief Operating Officer and Chief Financial Officer effective immediately. Mr. Prieb will also serve on the company's Board of Directors. He is a co-founder of Kleo Pharmaceuticals and the entrepreneur who secured its technology license from Yale University and organized the company's series A financing, which was led by Biohaven Pharmaceuticals.

"Roy's strategic insight and leadership have been key to putting Kleo on the path to success. He was one of the first people to recognize and articulate the value of our platform and has been a tremendous advocate for the company among investors and partners. We are excited to have him on board to help us execute our vision and lead this company to the next level," said David Spiegel, M.D. Ph.D., Chief Executive Officer at Kleo Pharmaceuticals.

"Kleo has the opportunity to reshape the field of immunotherapy and transform the lives of so many patients. We are looking forward to bringing together the right people and partners to advance our small molecule immunotherapies into the clinic. It will be an exciting journey and I am thrilled to be part of the team that will meet its challenges and deliver its successes," said Roy Prieb.

Roy Prieb is a technology entrepreneur with over 15 years of experience in business strategy, development, and operations. He has helped launch, fund, and grow several digital ventures including Saaspire, Kellogg Media Group, Qiosk.com, and JibJab.com. Earlier in his career, Mr. Prieb was a consultant with The Boston Consulting Group. He received his B.A. from Harvard University and M.B.A. from Wharton Business School.

About Kleo Pharmaceuticals Inc.
Kleo Pharmaceuticals Inc. is a biotechnology company initially formed on the basis of intellectual property from the Spiegel Lab at Yale University. The company was founded by Dr. David Spiegel and Roy Prieb is focused on developing a new class of targeted immunotherapies. The company is based in New Haven, CT. Further information regarding Kleo can be found at: http://kleopharmaceuticals.com.

About Biohaven Pharmaceuticals
Biohaven recently provided Series A funding to Kleo Pharmaceuticals, Inc. and entered into a master services agreement to provide clinical development support to help advance Kleo's small molecule, immune based therapeutics called Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMS). Biohaven is a privately-held biopharmaceutical company with expertise in late stage clinical development and has a portfolio of multiple late stage drug assets. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital. The company has advanced multiple candidates into the clinic and plans on pivotal trials beginning late 2016. Biohaven is owned by a group of investors including Yale University, Portage Biotech Inc. (OTC PINK: PTGEF) (CSE: PBT.U), John W. Childs and other private investors. Further information regarding Biohaven can be found at: http://biohavenpharma.com.

Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information